Business
Apellis Announces Investor Conference Call to Discuss Phase 3 PEGASUS Data to be Presented at the 25th Annual Congress of the European Hematology Association (EHA)
Conference Call Scheduled for Friday, June 12, 2020 at 8:30 a.m. ET WALTHAM, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:
About this update from Apellis Pharmaceuticals, Inc.
[{"type":"text","content":"Conference Call Scheduled for Friday, June 12, 2020 at 8:30 a.m. ET\nWALTHAM, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced it will host an investor conference call to discuss the detailed results from the Phase 3 PEGASUS study evaluating pegcetacoplan (APL-2), a targeted C3 therapy, compared to eculizumab in adults with paroxysmal nocturnal hemoglobinuria (PNH). The conference call will follow the virtual presentation of this data at the upcoming 25th Annual Congress of the European Hematology Association (EHA). The investor conference call is scheduled for Friday, June 12, 2020 at 8:30 a.m. ET and will feature members of Apellis management, as well as Peter Hillmen, M.B., Ch.B., Ph.D., PEGASUS study investigator and EHA presenter.\n Featured AbstractResults of the PEGASUS Phase III Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (S192). The presentation will be made available on-demand starting on Friday, June 12, 8:30 CET. Conference Call Information Apellis will host a conference call Friday, June 12, 2020 at 8:30 a.m. Eastern Time, to discuss the detailed Phase 3 PEGASUS study results. To access the conference call, please dial (866) 774-0323 (local) or (602) 563-8683 (international) at least 10 minutes prior to the start time and refer to conference ID 7291583. A live audio webcast of the call will be available under \"Events & Presentations\" in the Investor section of the Company's website, https://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 30 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. By pioneering targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology. For more information, please visit http://apellis.com. Apellis Forward-Looking Statement Statemen...